Click Chemistry

Cbz-Gly-Cit is a dipeptide linker containing a Cbz-protected amino group and may be used in the development of antibody drug conjugates (ADCs). The Gly-Cit peptide will undergo a selective cleavage by trypsin.

Gly-Cit can serve as a unprotected dipeptide linker in the synthesis of antibody drug conjugates (ADCs). The Gly-Cit peptide will specifically be cleaved by trypsin.

Cbz-Gly-Cit-PAB-OH is a dipeptide linker that incorporates a Cbz-protected amino group and can find application in the formulation of antibody-drug conjugates (ADCs). The Gly-Cit peptide will experience enzymatic cleavage by trypsin.

NH2-Gly-Cit-PAB-OH is an intermediate in the synthesis of the tripeptide Glu-Gly-Cit (EGCit) and may be conjugated in the creation of an antibody drug conjugate (ADC).

NH2-Glu-Gly-Cit-PAB-OH is a tripeptide linker which may be cleaved by cathepsins and is stable in mouse, monkey, and human plasma. It may function as an effective linker in the creation of antibody drug conjugates (ADCs).

Fmoc-PEG4-Glu-Gly-Cit-PAB-OH, a unique cleavable tripeptide linker, exhibits remarkable stability in the bloodstream, resisting degradation and human neutrophil protease cleavage, while still enabling the intracellular release of payloads in a discrete, traceless drug-release manner.

Fmoc-PEG4-Glu-Gly-Cit-PAB-PNP is a unique cleavable tripeptide linker, which can conjugate with an amine-containing paylaod. Fmoc group can be deprotected under basic conditions. This peptide exhibits remarkable stability in the bloodstream.

Fmoc-PEG4-Glu-Gly-Cit-PAB-MMAE is an antibody drug conjugate (ADC) precursor, including a cathepsin-cleavable Glu-Gly-Cit (EGCit) tripeptide, PABC linker, and MMAE payload. It can be attached to a monoclonal antibody (mAb) which directs it toward cancer cells. This peptide exhibits remarkable stability in the bloodstream. Also, it resists degradation and human neutrophil protease cleavage, while still enabling the intracellular release of payloads in a discrete, traceless manner.

Amino-PEG4-Glu-Gly-Cit-PAB-MMAE is an intermediate composed of a cleavable Glu-Gly-Cit (EGCit) peptide to build an antibody drug conjugate (ADC). It can be conjugated with a monoclonal antibody (mAb) to target cancer cells, showcasing exceptional stability in the bloodstream, resisting degradation and neutrophil protease cleavage. Moreover, it facilitates intracellular payload release discreetly and without a trace.